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Abstract
Background: The aim of this study was to investigate the impact of a tenofovir disoproxil fumarate (TDF) plus
ritonavir-boosted protease inhibitor (PI/r) regimen on renal function in Chinese HIV-infected patients.
Methods: Seventy-five HIV-1 infected patients failing first-line antiretroviral therapy (ART) comprised the TDF+PI/r
group. Seventy-five HIV-1 infected patients matched for gender, age, and renal function made up the control. All
subjects completed follow-up visits over 48 weeks. CD4 cell count, plasma HIV-1 viral load, and urine protein level
were assessed at the trial start (baseline, week 0) and at week 48. The serum creatinine and estimated glomerular
filtration rate (eGFR) were monitored at each follow-up point. Change in eGFR from baseline to week 48 was also
compared.
Results: Compared to control, the TDF+PI/r group exhibited higher levels of serum creatinine (79 vs. 69.7 μmol/L,
P<0.001) and a lower rate of eGFR (93.0 vs. 101.6 ml/min/1.73m2, P=0.009) at the end of week 48. Patients treated
with TDF+PI/r showed greater decline in eGFR than control (−8.8 vs. 6.4ml/min/1.73m2, P<0.001). Compared to
baseline renal function of the control group, the TDF+PI/r group exhibited a greater median decline in eGFR at the
end of week 48 (P<0.001).
Conclusions: We found that a TDF+PI/r based ART regimen resulted in greater renal function decline over 48
weeks. Therefore, renal function should be monitored especially when TDF is used in combination with PI/r.
Trial registration: ClinicalTrials.gov identifier: NCT00872417
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Background
Combined antiretroviral therapy (cART) has reduced the
mortality and morbidity associated with human immuno-
deficiency virus type 1 (HIV-1) infection and the risk of
HIV-infected patients’ progression to Acquired Immune
Deficiency Syndrome (AIDS). Side effects have been
reported in the past decades. Complications related to
long-standing HIV infection and treatment, such as the
nephrotoxic effects, have become the focus of researchers.
cART can itself cause renal toxic effects directly by
inducing acute interstitial nephritis, crystal nephropathy,
and renal tubular disorders [1]. cART can also contribute
to renal dysfunction indirectly via drug interactions. Kidney
damaged induced by the nucleotide analogue reverse
transcriptase inhibitor (NRTI) tenofovir is a well studied
drug that causes kidney damage in HIV patients. Tenofovir
was licensed for the treatment of HIV-infected patients
in the USA in 2001 [2], is well tolerated, and has no
evidence of long-term mitochondrial toxicity effects.
Tenofovir disoproxil fumarate (TDF) is recommended
as a first-line therapy in HIV treatment by both the
American Academy of HIV Medicine [3] and the European
AIDS Clinical Society [4].
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TDF is eliminated largely by glomerular filtration, and
20%-30% by active renal proximal tubular secretion [5].
Previous case reports reported TDF-associated renal
toxicity, including acute tubular necrosis [6], Fanconi
syndrome [7-9], and ultimately, renal failure [10] charac-
terized by a decline in glomerular filtration rates (GFRs)
and hypophosphatemia [11,12]. Studies with primarily
Caucasian patients report low rates of tenofovir-associated
nephrotoxicity, and severe renal impairment is rare in clin-
ical trials of tenofovir-containing first line antiretroviral
therapy (ART) regimens [13,14]. Recently, Alana Brennan
et al. reported that 2.4% South African (predominately
black) HIV patients receiving a tenofovir-containing
regimen experienced nephrotoxicity, and 7.8% died during
48 months of follow-up [15].
Little is known about renal safety of TDF in Asian
patients on tenofovir. TDF has been provided at no cost
by the Chinese government as a second-line therapy to
HIV-infected individuals who failed first-line treatment
since mid 2009. Moreover, the government has classified
TDF as a first-line therapeutic since 2012. It is thus urgently
necessary to determine TDF effects on renal function. In
this study, we report the outcome of a 48-week prospective
study on renal safety data of TDF plus ritonavir-boosted




This was a prospective, observational study conducted at
eight research centers in China. Patients were recruited
from several different regions of the country including
Beijing, Shanghai, Guangzhou, Shenzhen, Fuzhou, Henan,
and Yunnan provinces between November 2008 and
January 2010. Seventy-five HIV-1 infected patients with
first-line cART regimen treatment failure were enrolled
in the TDF+ ritonavir-boosted protease inhibitor (PI/r)
group. Patients all received second-line cart: TDF +
ritonavir-boosted lopinavir (LPV/r) + Lamivudine
(3TC). Inclusion criteria of this group included: (1) 18–65
years of age , (2) first-line cART failure defined as receiving
first-line cART (e.g., Thirty five patients treated with
Zidovudine (AZT) + 3TC + Nevirapine (NVP) / Efavirenz
(EFV), twenty patients treated with Stavudine (D4T) +
3TC + NVP / EFV, fifteen patients treated with AZT +
Didanosine (DDI) + NVP / EFV and five patients treated
with D4T + DDI + NVP / EFV.) for one year with plasma
HIV-1 viral load (VL) more than 1000 copies per milliliter
(cps/ml), and (3) available estimated glomerular filtration
rate (eGFR). The main exclusion criteria were (1) patients
who had received initial cART regimes containing TDF
and/or protease inhibitors (PIs) (2) serum creatinine >1.5
times the upper limit of normal, (3) eGFR< 50ml/min/
1.73m2, and (4) anticipated poor adherence. Seventy-five
HIV-1 infected cART-naïve patients matched for gender,
age, serum creatinine and eGFR were selected from a
multicenter cohort study population and made up the
control group. Control patients were given a cART
regimen of D4T/AZT+NVP+3TC. All subjects com-
plied to follow-up visits over 48 weeks from 2008 to
2010. To further investigate the influence of TDF+PI/
r-based cART regimens on renal function between
individuals with normal and abnormal renal function,
the TDF+PI/r group was divided into a normal renal
function (eGFR≥90 ml/min/1.73m2) sector and an abnor-
mal one (90>eGFR≥50 ml/min/1.73m2) based on eGFR
baseline. To note, the control group subjects were not on
an ART regimen, but TDF+PI/r patients were receiving
a first line ART regimen before the start, switching to a
second line ART regimen (TDF + 3TC+ LPV/r) at the
study’s beginning. Informed consent was obtained from
each participant. Ethics approval was obtained from the
Institutional Review Board of Peking Union Medical
College Hospital (PUMCH).
Measurements
The following clinical and laboratory data were collected
and recorded on case report forms: age, gender, race,
duration of HIV seropositive, weight, height, hypertension,
diabetes mellitus, smoking, CD4+ cell count, plasma HIV-1
viral load, urine protein level, serum creatinine, and eGFR.
Hypertension was defined as either blood pressure greater
than 140/90mm Hg on at least two of any three preliminary
clinic visits, or the use of an antihypertensive medication.
Diabetes mellitus was defined by physician diagnosis or by
patient use of an antidiabetic agent. CD4 cell count, plasma
HIV-1 viral load, and urine protein level were monitored
at start and week 48. Serum creatinine and eGFR were
monitored at start and at weeks 0, 4, 8, 12, 24, 36, and 48.
Change in eGFR from week 0 to 48 for TDF+PI/r and
control groups was compared. Urine protein level and
serum creatinine were administered by PUMCH clinical
laboratory departments. The eGFR was calculated
using the four-variable Modification of Diet in Renal
Disease (MDRD) [16]. Urine protein was measured by
a urine dipstick. Proteinuria was defined as ≥1+ on a
urine dipstick. The CD4+ cell count was detected from
Ethylenediaminetetraacetic acid (EDTA)-anticoagulated
whole blood by FACS-Calibur (BD Biosciences, NJ, USA)
using standard techniques according to the manufacturer’s
protocol. Separated plasma was immediately frozen
at −80°C and transported to PUMC Hospital’s central
laboratory for viral load testing using the COBAS
Ampliprep/TaqMan 48 real-time reverse transcription
PCR (RT-PCR) (Roche, CA, USA) according to manufac-
turer’s instructions. The assay working range was between
40 and 1,000,000 cps/ml.
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Statistical analysis
All analyses were performed on the intent-to-treat (ITT)
population. Missing values were imputed for the analysis
with the last-observation-carried-forward method. Con-
tinuous variables were assessed with the Student’s t test
or Mann–Whitney test appropriately. Categorical variables
were assessed with the Chi-square test. Differences in
changes in serum creatninine and eGFR at 48 weeks were
assessed using the Wilcoxon rank sum test to compare
median values of continuous data. Absolute differences for
each group in serum creatinine and eGFR were respectively
analyzed during the follow-up using repeated measures
of variance. The Wilcoxon signed rank test was used to
assess trends in serum creatinine or eGFR during the
follow-up. For all tests, a P-value less than 0.05 was
considered statistically significant. Statistical analysis
was conducted via SPSS version 16.0 (SPSS Inc., Chicago,
IL, USA).
Results
A summary of patient characteristics in both TDF+PI/r
and control groups are summarized in Tables 1 and 2.
Patients were well matched, with no wide demographic
variation between cohorts. Further, no significant differ-
ences in hypertension, diabetes, smoking, body mass index
(BMI), CD4+ cell count, plasma HIV-1 viral load, and
urine protein level were detected (Table 1). The duration
of HIV seropositive was significantly longer in TDF+PI/r
patients compared to control (median [inter-quartile
range, IQR], 65[26–139] vs. 22[19–34] months, P<0.001).
Using intent-to-treat (ITT) analysis at the end of week
48, TDF+PI/r patients exhibited higher levels of serum
creatinine (median[IQR], 79.0[70.0-85.0] vs. 69.7[62–80.3]
μmol/L, P<0.001) and a significantly lower rate of eGFR
(median[IQR], 93.0[82.4-104.0] vs. 101.6[86.8-121.6] ml/
min/1.73m2, P=0.009). BMI was similar for TDF+PI/r and
control groups (median[IQR], 21.9[20.1-23.7] vs. 21.0
[19.3-22.9] kg/m2, P=0.083). No difference was noted in
CD4 cell count (median[IQR], 279[196–380.5] vs. 292.0
[207.0-394.0] cells/μl, P=0.736) or HIV-1 RNA viral load
(median[IQR], 1.6[1.6-1.8] vs. 1.6[1.6-1.7] log10 copies/ml,
P=0.064). Importantly, however, median eGFR did change
from start to 48 weeks for TDF+PI/r patients vs. control
(median[IQR], -8.8[−18.5-3.3] vs. 6.4[−3.8-16.5] ml/min/
1.73m2, P<0.001). Patients treated with TDF+PI/r showed
declining eGFR levels.
The changes in serum creatinine concentrations during
the 48 week follow-up period are shown in Figure 1. For
control, median serum creatinine concentrations varied
between 69.7 and 72.0 ml/min/1.73m2 for baseline and
the 48-week point, respectively, and there existed no
significant differences at each follow-up point in between
(P=0.638). For the TDF+PI/r group, the median [IQR]
serum creatinine concentration was 71.0 [65.0-81.0] μmol/L
at baseline, and varied between 78.0 and 81.0 μmol/L
between 4 and 48 weeks. We found that compared with
baseline, the median values of serum creatinine for the
4-week point were significantly higher in TDF+PI/r
group (median [IQR], 71.0 [65.0-81.0] vs.78.0 [70.0-85.0]
μmol/L) (P=0.002). However, the median values of serum
creatinine between the 4-week point and the 48-week
point were no significant differences in TDF+PI/r group
(median [IQR], 78.0 [70.0-85.5] vs.79.0 [70.0-85.0] μmol/L)
(P=0.719). So it demonstrated that the values of serum
creatinine increased significantly initially (0–4 weeks),
and then (5-48weeks) maintained at the stable level in
TDF+PI/r group.
Changes in eGFR during the 48 week follow-up are
shown in Figure 2. For control, median eGFR varied
between 96.9 and 105.1 ml/min/1.73m2 with no significant
differences at each follow-up point. For the TDF+PI/r







Male 58(77.3) 53(70.7) 0.352
Age (years) 44 (41–50) 42 (34–53) 0.322
Race 0.363
Han 74 (98.7) 71 (94.7)
Other 1 (1.3) 4 (5.3)
Duration of HIV seropositive
(months)
65 (26–139) 22 (19–28) <0.001
Smoking









BMIb (kg/m2) 21.6 (20.1-23.5) 20.6 (19.5-23.0) 0.129
CD4 cell count (cells/μl) 157(63–267) 185 (104–259) 0.509
Viral load (log10 copies/ml) 4.4 (3.7-4.8) 4.5 (3.9-4.9) 0.117
Proteinuria 0.631
Positive 11(14.7) 9 (12)
Negative 64(85.3) 66 (88)
Serum creatinine (μmol/L) 71(65–81) 71.4(62–81.7) 0.263
eGFRc(ml/min/1.73 m2) 101.6 (85.6-117.2) 105.1 (76.8-110.3) 0.376
Note.
aValues are expressed as median (interquartile range) or number (percentage).
bBMI =weight (kg)/(height (m))2.
ceGFR = 186 × (Serum creatinine (mg/dL))-1.154 × (age(years))-0.203 × (0.742 if female).
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group, median [IQR] starting eGFR was 101.6[85.6-117.2]
ml/min/1.73m2 and varied between 88.8 and 94.2 ml/min/
1.73m2 between 4 and 48 weeks. Compared with baseline,
the median eGFR for the 4-week point were significantly
lower in TDF+PI/r group (median [IQR], 101.6[85.6-117.2]
vs. 90.4[82.8-103.4] ml/min/1.73m2) (P=0.001). However,
the median values of eGFR between the 4-week point
and the 48-week point were no significant differences in
TDF+PI/r group (median [IQR], 90.4[82.8-103.4] vs.
93.0[82.4-104.0] ml/min/1.73m2) (P=0.725). So it showed
that the median values of eGFR decreased significantly
initially (0–4 weeks), and within 5–48 weeks, median
eGFR remained relatively stable in participants treated
with TDF + LPV/r + 3TC. We also calculated creatinine
clearance (CrCl) using the Cockcroft–Gault equation, and
saw a similar trend, as eGFR changes throughout the 48
weeks between the two groups (data not shown).
To further analyze the impact of TDF+PI/r-based cART
regimens on renal function between renal function normal
and abnormal patients, 75 TDF+PI/r patients were stratified
by kidney function into normal (eGFR≥90 ml/min/1.73m2)
or abnormal (90>eGFR≥50 ml/min/1.73m2) groups: 52
Table 2 Characteristics of patients in TDF+PI/r and control groups at the end of 48 weeeksa
Variable TDF+PI/r group (n=75) Control group (n=75) P
BMIb (kg/m2) 21.9 (20.1-23.7) 21.0 (19.3-22.9) 0.083
CD4 cell count (cells/μl) 279 (196–380.5) 292.0 (207.0-394.0) 0.736
Viral load (log10 copies/ml) 1.6 (1.6-1.8) 1.6 (1.6-1.7) 0.064
Proteinuria 0.071
Positive 9 (12) 3(4)
Negative 66 (88) 72 (96)
Serum creatinine (μmol/L) 79 (70–85) 69.7 (62–80.3) <0.001
eGFRc (ml/min/1.73 m2) 93.0 (82.4-104.0) 101.6 (86.8-121.6) 0.009
Change in eGFR (ml/min/1.73 m2) −8.8(−18.5-3.3) 6.4(−3.8-16.5) <0.001
Note.
aValues are expressed as median (interquartile range, IQR) or number (percentage).
bBMI =weight (kg)/(height (m))2.
ceGFR = 186 × (Serum creatinine (mg/dL))-1.154 × (age(years))-0.203 × (0.742 if female).
0w 4w 8w 12w 24w 36w 48w
TDF+PI/r n=75 n=75 n=71 n=73 n=71 n=67 n=69
Control n=74 n=74 n=71 n=73 n=73 n=70 n=72
Figure 1 Changes in median serum creatinine concentrations at 0, 4, 8, 12, 24, 36, and 48 weeks in TDF+PI/r and control groups.
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and 23 patients were respectively divided into these
groups. Significant differences in eGFR levels between
these groups at baseline (median[IQR], 112.7[100.9-121.3]
vs. 81.4[76.9-85.4], P<0.001) and at week 48 (median
[IQR], 97.7 [86.9-110.3] vs. 84.2[70.6-94.5], P<0.001) were
observed. Changes in median eGFR during 48 weeks of
TDF+PI/r-based cART treatment between the two groups
are shown in Figure 3. As Figure 3 highlights, baseline
eGFR normal patients showed greater changes in median
eGFR than baseline eGFR abnormal patients at week 4, 8,
12, 24, 36, and 48 (P<0.001), but renal function always
fluctuated within normal range. For eGFR abnormal
patients, no significant differences in median eGFR
were found at 0, 4, 8, 12, 24, 36, and 48 weeks. For
these patients, magnitude of eGFR decline was mild, and
severe renal dysfunction was not observed during follow-up.
Baseline eGFR normal patients exhibited greater decline in
eGFR than eGFR abnormal patients at 4, 8, 12, 24, 36, and
48 weeks, but renal function still fluctuated within the
normal range. For two (8.7%) patients, eGFR decreased to
less than 50ml/min/1.73m2, but severe renal dysfunction
was not detected during the 48 week follow-up. After 48
weeks, no significant difference in proteinuria incidence
between the two groups (12% vs. 4%, P=0.071) was
apparent.
Discussion and conclusions
Here, we present novel data on the influence of TDF
combination with PI/r cART regimens on renal function
in Chinese adult HIV-infected patients over a 48 week
period. We found that patients exposed to TDF + LPV/r +
3TC exhibited higher levels of serum creatinine, a lower
eGFR rate, and greater renal function decline than control.
Importantly, our data demonstrated that serum creatinine
rapidly increased, while eGFR remarkably declined during
the first 4 weeks.
Only a few patients can afford the cost of TDF if TDF
was used as first-line therapy drug. Patients who failed
first-line treatment could receive cART containing TDF
because TDF was a free second-line therapy provided by
the Chinese government to HIV-infected individuals
who failed first-line treatment since mid-2009. Patients
in the TDF group were infected with HIV for longer
than control, and were previously exposed to ART
agents. Although patients in the TDF group were HIV
seropositive longer, they received first-line cART (e.g.,
AZT + 3TC +NVP/EFV, D4T + 3TC + NVP/EFV, AZT +
DDI + NVP/EFV or D4T + DDI + NVP/EFV) for over a
year. To our knowledge, first-line therapies mentioned
previously were not known to be associated with renal
damage. However, using cART and suppressing HIV RNA
may improve kidney function [17], reduce the rate of
eGFR decrease [18], and/or reduce the risk of renal events
[19]. Patients who received initial cART regimes containing
TDF and/or PIs were excluded from our study, and
baseline serum creatinine, eGFR and HIV-1 RNA viral
load were not significantly different between TDF+PI/r
and control groups.
Nancy Crum-Cianflone et al. [20] evaluated the impact































0w 4w 8w 12w 24w 36w 48w
TDF+PI/r n=75 n=75 n=71 n=73 n=71 n=67 n=69
Control n=74 n=74 n=71 n=73 n=73 n=70 n=72
Figure 2 Changes in median eGFR at 0, 4, 8, 12, 24, 36, and 48 weeks in TDF+PI/r and control groups.
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among 150 HIV-infected Caucasian patients Initiating
both tenofovir and boosted PI therapy greatly impacted
kidney function: 78 (52%) of subjects showed a reduction
in eGFR, the median change being −12.1 ml/min/1.73m2
[95% confidence interval (CI), -9.1 to −14.1 ml/min/
1.73m2]. Moreover, 30% lost >10 mL/min/1.73m2 during
the 2-year follow-up period. Goicoechea et al. [21] com-
pared the estimated decline in renal function among
Western HIV-1 infected patients receiving either TDF+PI/
r- (n=51) or non-TDF- containing (n=66) regimens. They
demonstrated that TDF+PI/r patients showed a greater
rate of decline in creatinine clearance (CrCl) than the
non-TDF-containing group (for MDRD, -14.7 vs. -4.78
mL/min/1.73m2/year). Consistent with observations in the
Western population, median changes of eGFR were −8.8
ml/min/1.73m2 in TDF+PI/r and 6.4 ml/min/1.73m2 in
control. Patients treated with TDF and PI/r showed
greater decline in renal function over 48 weeks compared
to non-TDF-containing regimens. Gallant JE et al. also
illustrated that patients taking TDF and a PI/r exhibited a
greater median decline in eGFR than those taking TDF
and a non-NRTI at 6 months, with trends at 12 and 24
months [12]. Data from the HIV Outpatient Study (HOPS)
cohort, however, showed no differences in rate of creatinine
clearance at 12 months between patients who were treated
with either tenofovir, non-NRTIs, or ritonavir-boosted
protease inhibitors (atazanavir or lopinavir) [22]. A smaller
renal function change in PI/r-treated patients may result
from differences in patient characteristics. Compared with
the HOPS cohort, only antiretroviral-experienced patients
age 18–65 with eGFR more than 50 ml/min/1.73m2 and
less advanced HIV disease were included in our study.
Moreover, the comparator group contained both TDF- and
other PI+TDF-treated patients. This may have influenced
the decreased renal function observed in their study,
reducing the window to discern an effect between
treatment groups.
For tenofovir-induced nephrotoxic effects, approximately
70% are observed with concomitant use of low-dose rito-
navir [1]. Due to a PI/r and tenofovir interaction, renal
clearance of tenofovir is retarded. Kiser JJ et al. observed
that patients taking tenofovir + LPV/r showed a 17.5%
lower tenofovir renal clearance than those taking TDF
alone, even after adjusting for GFR differences [23]. The
plasma concentration of tenofovir can be increased by
approximately 20-37% in PI/r-containing regimens [24,25].
Studies have also highlighted that ritonavir is a potent
inhibitor of multidrug resistance-associated protein 2
(MRP-2) [26]. Postulated mechanisms include a potential
unidentified cofactor normally excreted by MRP2 potentiat-
ing TDF toxicity or competing for TDF excretion at MRP4
[27]. Whether this mechanism is due to PI/r competitively
inhibiting renal tubular transporter function, decreasing
TDF renal excretion needs further elucidation.
0w 4w 8w 12w 24w 36w 48w
eGFR ≥ 90 group n=52 n=52 n=51 n=51 n=51 n=46 n=47
90 eGFR≥ 50 group n=23 n=23 n=20 n=22 n=20 n=21 n=22>
Figure 3 Changes in median eGFR over time in the TDF+PI/r group, by eGFR normal (eGFR≥90 ml/min/1.73m2) and abnormal
(90>eGFR≥50 ml/min/1.73m2) baselines.
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For our analyses of kidney function over time among
patients using TDF+LPV/r+3TC, the impact of TDF+ PI/r
was apparent within the first 4 weeks and stabilized to 48
weeks. Consistent with an observation from a Development
of Antiretroviral Therapy (DART) trial in a large cohort of
HIV-infected African adults from Uganda and Zimbabwe,
changes in eGFR were also observed predominantly during
early exposure to TDF cART regimens, with kidney
function stabilization after ~4 weeks [28]. Contrastingly,
in the EuroSIDA (AIDS across Europe) study, data from
larger European cohorts have demonstrated an association
between TDF cumulative exposure and renal toxicity
increases [29]. Andrew N. Phillips et al. performed a
prospective study comprised of 85% white patients. 89.8%
of enrolled participants were cART-experienced patients,
and 99.7% of patients were already receiving a TDF-
containing cART regimen. Many enrolled participants
exhibited preexisting risk factors for CKD. In the TDF
group, 21.7% patients were using nephrotoxic drugs, such as
pentamidine, cidofovir, acyclovir, foscarnet, or amphotericin
B at or before the trial’s start.
In our study, patients were Chinese, and 90% were of
the Han race. All patients in TDF+PI/r group had never
taken TDF and/or PIs-containing cART regimens, nor
did they use nephrotoxic drugs prior to the trial. Thus, a
plausible explanation for this discrepancy resides in the
longer follow-up of the EuroSIDA cohort, genetics,
difference in treatment history, and inclusion patients
who may have had pre-existing risk factors for CKD,
subsequently increasing the risk of TDF-related CKD.
The impact of a TDF+PI/r-based cART regimen on renal
function was analyzed in patients stratified by baseline
eGFR. Baseline eGFR was divided into two categories
(eGFR≥90 and 90>eGFR≥50 ml/min/1.73m2). We expect
an observable significant decline in patients’ renal function
whose baseline is 90>eGFR≥50 ml/min/1.73m2. We were
thus surprised to detect no significant differences in
median eGFR at 0, 4, 8, 12, 24, 36 and 48 weeks for
patients with baseline 90>eGFR≥50 ml/min/1.73m2.
Perhaps patients with this basal eGFR remain insensitive
to nephrotoxic side effects, but may be hypersensitive to
renal dysfuntion. Our cutoff for group sorting may be too
broad to detect eGFR changes, since TDF impact on GFR
is normally small. Studies confirming our hypotheses
require further elucidation.
Early detection and diagnosis of renal dysfunction are
essential for preventing or at least slowing kidney function
decline to ultimately improve outcome in HIV-infected
patients. Individuals with underlying impaired kidney
function and patients whose kidney damage was drug-
induced would likely benefit from vigilant renal follow-up.
Particularly, patients receiving tenofovir may benefit from
frequent assessments of kidney function, serum phosphate
levels, and urinalyses to monitor for early signs of
nephrotoxicity [6,30]. The HIV Medicine Association of
the Infectious Diseases Society of America (IDSA) recom-
mends that patients receiving TDF meet any of three
criteria: eGFR<90 mL/min/1.73 m2, use of medications
eliminated through renal secretion, comorbid diseases
following a ritonavir-boosted protease inhibitor regimen,
should have kidney function (via eGFR) and serum phos-
phate measured no less frequently than every 6 months,
and also should be analyzed for proteinuria and glycosuria
[31]. Evidence is lacking in instructing patients about
frequency of assessment. In agreement with the IDSA, our
results suggest that eGFR should be monitored over the
first 4 weeks of follow-up when TDF is combined with PI/r.
Patients who exhibited decrease eGFR with TDF+PI/r
probably are candidates for more frequent assessment of
kidney function, serum phosphate levels, and urinalyses,
and additionally have their kidney function evaluated for a
longer term. TDF+PI/r-based cART regimens should be
carefully considered in patients with decreased kidney
function.
Our study reports that incidences of proteinuria were
not significant for both groups at weeks 0 or 48. Tenofovir
is thought to primarily affect proximal renal tubular func-
tion [32], yet glomerular function may be lightly affected,
so proteinuria incidences were not noticeable in urine.
Our study does have limitations. First, patients in the
TDF+ PI/r group were receiving first-line cart prior to
the study, while control patients were naïve. Second,
only 3 patients older than 60 were enrolled. This study
was thus not designed to decipher an effect of TDF on
renal function of older patients, and the safety of TDF
on older patients should be assessed in the future. Third,
patients whose serum creatinine > 1.5 times the upper
limit of laboratory normal and/or eGFR< 50ml/min/
1.73m2 were excluded from our study. The influence of
TDF based cART regimens on renal function in HIV-1 with
compromised renal function remains poorly understood.
Patients with renal dysfunction treated with TDF cART
regimens should be frequently monitored by nephrologists.
Finally, our last time point was 48 weeks. Further follow-up
in a larger cohort would be required to more accurately
determine long-term TDF-related nephrotoxicity. In view
of these limitations, a prospective long-term multicenter
clinical trial is being considered to investigate the potential
impact of TDF on renal function in Chinese HIV-infected
individuals. Future trials may include older patients and
patients with moderate to severe renal dysfunction.
In conclusion, TDF+PI/r based cART regimens were
associated with a higher level of serum creatinine and a
greater decline in renal function over 48 weeks compared
to control. For patients with baseline eGFR ≥90 ml/min/
1.73m2, TDF+PI/r based cART regimens could influence
non-progressive eGFR decreases, but the impact of
TDF+PI/r based cART regimens on eGFR in patients with
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abnormal renal function seemed to be relatively minor.
Additionally, renal function rapidly decreased during the
first four weeks. Our results suggest that renal function
should be monitored over the first four weeks of follow-up,
especially when TDF is combined with PI/r.
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